The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular edema

被引:12
|
作者
Cicinelli, Maria Vittoria [1 ,2 ]
Rosenblatt, Amir [3 ,4 ]
Grosso, Domenico [2 ]
Zollet, Piero [2 ]
Capone, Luigi [2 ]
Rabiolo, Alessandro [2 ,5 ]
Lattanzio, Rosangela [2 ]
Loewenstein, Anat [3 ,4 ]
Bandello, Francesco [1 ,2 ]
机构
[1] Univ Vita Salute San Raffaele, Sch Med, Milan, Italy
[2] IRCCS San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy
[3] Tel Aviv Sourasky Med Ctr, Div Ophthalmol, Tel Aviv, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[5] Gloucestershire Hosp NHS Fdn Trust, Dept Ophthalmol, Cheltenham, Glos, England
关键词
VITREOUS INSERTS; MANAGEMENT; RANIBIZUMAB; EFFICACY; BENEFIT; RETINA; 3-YEAR; SAFETY;
D O I
10.1038/s41433-020-01373-1
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background/Objectives To investigate if the visual and anatomic response to the first dexamethasone implant (DEX) predicts the 12-month clinical outcome after shifting to fluocinolone acetonide (FAc) implant in patients with diabetic macular oedema (DMO). Methods Retrospective cohort study including pseudophakic patients with previously treated DMO, undergone one or more DEX injections before FAc. Functional and morphologic response to DEX was defined based on the best-corrected visual acuity (BCVA) and central macular thickness (CMT) changes after the first DEX, respectively. Steroid-response was defined as intraocular pressure (IOP) elevation >= 5 mmHg or IOP > 21 mmHg after any previous DEX exposure. Pairwise comparisons for BCVA, CMT, and IOP after FAc were performed with linear mixed models and a repeated-measure design. Results Forty-four eyes of 33 patients were included. Patients were shifted to FAc after a mean +/- standard deviation of 4.6 +/- 3.2 DEX injections. Overall, BCVA and CMT improved during the first 12 months after switching to FAc (p = 0.04 and p < 0.001, respectively). Only eyes with a good morphologic response to DEX had a significant CMT reduction after FAc (p < 0.001), while no significant relationship was found between BCVA improvement after DEX and after FAc. IOP elevation occurred in 9 eyes (20%) following DEX implant. These eyes carried a 20-fold increased risk of having an IOP rise after FAc (p < 0.001), with a non-linear relationship between the IOP increase after DEX and the one after FAc. Conclusion The response to previous DEX may anticipate the morphologic response to subsequent FAc. Eyes with steroid-induced IOP elevation after DEX are at a high risk of IOP increase after FAc. The visual response after FAc was not associated with the visual response to previous steroids, indicating that FAc may have a role also in patients refractory to DEX implant.
引用
收藏
页码:3232 / 3242
页数:11
相关论文
共 50 条
  • [31] Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema
    Soubrane, G.
    Behar-Cohen, F.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2015, 38 (02): : 159 - 167
  • [32] Effective Duration of Fluocinolone Acetonide (FAc) Implant in the Treatment of Diabetic Macular Edema
    Saigal, Khushi
    El Hamichi-Potamkin, Sophia
    Khurshid, Syed Gibran
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [33] Efficacy of dexamethasone intravitreal implant for the treatment of diabetic macular edema
    Bonnin, Sophie
    Dupas, Benedicte
    El Sanharawi, Mohamed
    Perol, Julien
    Erginay, Ali
    Tadayoni, Ramin
    Massin, Pascale
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2015, 25 (05) : 448 - 453
  • [34] Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME)
    McCluskey, Jessica D.
    Kaufman, Paul L.
    Wynne, Kathy
    Lewis, Gregory
    INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, 2019, 12 : 93 - 102
  • [35] Comparison of dexamethasone intravitreal implant and intravitreal triamcinolone acetonide for the treatment of pseudophakic cystoid macular edema in diabetic patients
    Dang, Yalong
    Mu, Yalin
    Li, Lin
    Mu, Yahui
    Liu, Shujing
    Zhang, Chun
    Zhu, Yu
    Xu, Yimin
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 1441 - 1449
  • [36] REPEATED INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX) FOR DIABETIC MACULAR EDEMA
    Scaramuzzi, Matteo
    Querques, Giuseppe
    La Spina, Carlo
    Lattanzio, Rosangela
    Bandello, Francesco
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2015, 35 (06): : 1216 - 1222
  • [37] Intravitreal dexamethasone implant for diabetic macular edema : a retrospective study
    Bensoussan, Elsa
    Gastaud, Pierre
    Baillif, Stephanie Agnes
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [38] Short Term Results of Fluocinolone Acetonide Intravitreal Implant (Iluvien®) for Diabetic Macular Edema in Highly Treated Eyes
    Dhawlikar, Nisha
    Shah, Sumit P.
    Yarian, David L.
    Prenner, Jonathan L.
    Friedman, Eric S.
    Fine, Howard F.
    Wheatley, H. Matthew
    Roth, Daniel B.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [39] Dexamethasone intravitreal implant for diabetic macular edema in a pregnant patient
    Yoo, Romi
    Kim, Hyung Chan
    Chung, Hyewon
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2016, 9 (10) : 1524 - 1527
  • [40] Intravitreal Dexamethasone Implant in Patients with Refractory Diabetic Macular Edema
    Frascio, Pietro
    Allavena, Francesca
    Nicolo, Massimo
    Telani, Serena
    Traverso, Carlo
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)